Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
35 results
- 1상모집 예정· HealthySB35(익세키주맙 바이오시밀러)와 탈츠의 약동학, 안전성, 내약성 및 면역원성 비교 연구
A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants
리드: 삼성바이오에피스
- 2상완료· Age-Related Macular DegenerationA Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
리드: 삼성바이오에피스
- 1상모집 중· Advanced Solid TumorsA Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
리드: 삼성바이오에피스
- 3상모집 중단 (진행 중)· Non-small Cell Lung Cancer Stage IVA Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
리드: 삼성바이오에피스
- 1상모집 중단 (진행 중)· Non-small Cell Lung Cancer Stage IIA Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
리드: 삼성바이오에피스
- 2상완료· Neovascular Age-related Macular DegenerationA Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
리드: 삼성바이오에피스
- 4상상태 미확인· Breast CancerNeoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
협력: 삼성바이오에피스
- 3상완료· Postmenopausal OsteoporosisA Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
리드: 삼성바이오에피스
- 3상완료· Neovascular Age-related Macular DegenerationA Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
리드: 삼성바이오에피스
- 3상완료· Paroxysmal Nocturnal HemoglobinuriaA Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
리드: 삼성바이오에피스
- 4상상태 미확인· Rheumatoid ArthritisTargeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification
협력: 삼성바이오에피스
- 3상완료· Age-Related Macular DegenerationA Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
리드: 삼성바이오에피스
- 단계 미표기완료· Rheumatoid ArthritisObservational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel
협력: 삼성바이오에피스
- 3상완료· Lung CancerA Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
리드: 삼성바이오에피스
- 단계 미표기조기 종료· Breast NeoplasmsA Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
리드: 삼성바이오에피스
- 3상완료· Rheumatoid ArthritisA Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
리드: 삼성바이오에피스
- 3상완료· HER2 Positive Early or Locally Advanced Breast CancerA Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
리드: 삼성바이오에피스
- 3상완료· Rheumatoid ArthritisA Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
리드: 삼성바이오에피스
- 3상완료· Rheumatoid ArthritisA Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
리드: 삼성바이오에피스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.